Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alphamab Oncology

http://www.alphamabonc.com/

Latest From Alphamab Oncology

Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates

Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.

Deal Watch Business Strategies

China Signals Further Clinical Trial Policy Tightening

The nation’s top drug regulator vows to adopt ICH’s guidelines on drug safety and efficacy, after dropping the industry a bombshell with the tightening of oncology drug clinical trials a week ago.

China Clinical Trials

As China Prices Drop, Junshi Looks To Coherus To Take PD-1 Global

After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.

China Deals

Affordable PD-1 From China? CStone Going Global With EQRx Onboard

As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.

Commercial ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Alphamab Biopharmaceuticals Co., Ltd.
    • Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
    • Suzhou Alphamab Co., Ltd.
UsernamePublicRestriction

Register